# SPINRAZA (nusinersen) Access
Keywords: SPINRAZA, nusinersen, SMA, 5q spinal muscular atrophy, paediatric treatment, adult treatment, motor function, NICE, clinical trials

> This page provides information about SPINRAZA (nusinersen), a treatment for 5q spinal muscular atrophy (SMA), including its efficacy, safety, clinical trials, and access to treatment centers for both paediatric and adult patients in the UK and Ireland.

## Details
- [SPINRAZA Overview](#): SPINRAZA is a treatment for 5q SMA, the most common form of the disease, with demonstrated efficacy and a well-tolerated safety profile.
- [Paediatric Treatment Centres](#): Lists 18 paediatric treatment centers across the UK and Ireland for SMA services.
- [Adult Treatment Centres](#): Provides details on 12 adult treatment centers offering SMA services in the UK and Ireland.
- [Why Refer Patients Without Delay](#): Highlights the importance of early referral to maximize SPINRAZA’s benefits, including motor function improvements and disease stabilization.
- [Efficacy in Paediatric Patients](#): Emphasizes early treatment benefits, including achieving motor function milestones closer to normal development in pre-symptomatic SMA patients.
- [Efficacy in Adult Patients](#): Real-world data shows SPINRAZA helps stabilize SMA and provides better outcomes for patients with residual motor function.
- [Nurture Clinical Trial](#): Describes an ongoing phase 2 study evaluating SPINRAZA in pre-symptomatic SMA patients.
- [Hagenacker Study](#): Details a 10-centre observational study on SPINRAZA’s safety and efficacy in adults with 5q SMA.
- [NICE Reimbursement](#): SPINRAZA is reimbursed by NICE for SMA types I, II, and III under managed access criteria.
- [Measures of Motor Function](#): Explains motor function measures used in SPINRAZA clinical studies, including HFMSE, RULM, and CHOP INTEND.
- [Adverse Event Reporting](#): Provides guidance on reporting adverse events in the UK and Ireland.